Back to search

Switzerland· 67446001

Rybelsus 3 mg, Tabletten

A semaglutide product, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC A10BJ06

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedRybelsus 3 mg, TablettenATCA10BJ06REGISTER NO.67446001PACKS LISTED1CHECKEDAugust 9, 2026

Where it is registered

Semaglutide is registered in 14 of 19 countries.

Countries holding a registration under ATC A10BJ06 (semaglutide), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Semaglutide · ATC A10BJ06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of semaglutide costs, country by country.

Normalised to the WHO defined daily dose (10.5 mg), the median price runs from $11.85 in Italy to $430.99 in Switzerland — a ×36 gap.

  • Switzerland: $430.99 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Semaglutide · price per daily dose (10.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$430.99
  • IT Italy$11.85
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Manufacturer
Novo Nordisk Pharma AG
Country
Switzerland (CH)
ATC code
A10BJ06
ATC class
Semaglutide
Defined daily dose
10.5 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
August 9, 2026

Packs & prices · 1

1 priced
  • gtin
    7680674460015
    Blist 30 Stk
    CHF 113.5

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

301 interactions on record for semaglutide.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Semaglutide · interactions on record

301 records

  • 3 severe
  • 258 moderate
  • 40 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dac6016e-5038-4280-81d8-ff0cef0878da
GET /v1/drugs/dac6016e-5038-4280-81d8-ff0cef0878da?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "semaglutidum 3 mg",
  "valid_from": "2022-10-01",
  "limitations": "[{\"description\":\"Zur Behandlung von Patienten mit einem unzureichend kontrollierten Typ 2 Diabetes mellitus ergänzend zu Diät und Bewegung:<br>\\n- In Monotherapie bei Patienten mit nachgewiesener Kontraindikation oder nachgewiesener Unverträglichkeit für Metformin.<br>\\n<br>\\nZur Behandlung von Patienten mit einem Typ 2 Diabetes mellitus in Kombination mit folgenden Therapieoptionen, wenn durch diese Antidiabetika keine ausreichende Blutzuckerkontrolle erreicht wird:<br>\\n- Als Zweifachkombination mit Metformin oder einem Sulfonylharnstoff<br>\\n- Als Dreifachkombination mit einer Kombination aus Metformin und einem Sulfonylharnstoff<br>\\n- In Kombination mit Basalinsulin mit oder ohne Metformin<br>\\n- In Kombination mit einem SGLT-2-Inhibitor mit oder ohne Metformin<br>\\n<br>\\nMindestens BMI 28. Zusätzliche Medikamente zur Gewichtsreduktion werden nicht vom Krankenversicherer vergütet.<br>\\n<br> \\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-12-01\",\"validTo\":null}]",
  "galenic_form": "Tabl 3 mg (alt)",
  "therapeutic_area": null,
  "sl_inclusion_date": "2020-08-01",
  "self_retention_pct": 10
}

See everything about semaglutide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.